Table 1.
Clinical and demographic characteristics of the cohort by disease activity group as measured by DAS28ESR category: mean ± standard deviation or frequency (%).
| DAS28ESR Disease Activity Categorya,b | |||
|---|---|---|---|
| Whole Cohort | Low | Moderate/High | |
| Number of | 161 (100%) | 39 (24%) | 122 (75%) |
| Age at DXA (years) | 62.4 ± 10.2 | 61.8 ± 10.2 | 62.6 ± 10.2 |
| Female | 142 (88%) | 31 (79%) | 111 (91%) |
| Race/Ethnicity | |||
| Hispanic/Latino | 73 (45%) | 12 (31%) | 61 (50%) |
| Asian | 59 (37%) | 15 (38%) | 44 (36%) |
| Other | 29 (18%) | 12 (31%) | 17 (14%) |
| RA duration (years) | 10.5 ± 7.3 | 9.6 ± 7.6 | 10.8 ± 7.2 |
| RF positive | 139 (88%) | 35 (90%) | 104 (87%) |
| ACPA positive | 125 (83%) | 32 (84%) | 93 (83%) |
| BMI (kg/m2) | 28.3 ± 5.8 | 27.0 ± 4.8 | 28.7 ± 6.0 |
| Prednisone (mg/day)b | 3.7 ± 3.6 | 2.0 ± 2.2 | 4.3 ± 3.9 |
| csDMARD ever | 157 (98%) | 39 (100%) | 118 (97%) |
| csDMARD usec | 82.8 ± 23.8 | 86.7 ± 20.0 | 0.8 ± 0.2 |
| bDMARD ever | 101 (63%) | 20 (51%) | 81 (67%) |
| bDMARD usec | 35.8 ± 37.1 | 33.7 ± 40.7 | 36.4 ± 36.0 |
| OP medication use (ever) | 93 (58%) | 16 (41%) | 77 (63%) |
| Number of Study visits | 16.8 ± 10.9 | 16.1 ± 12.0 | 17.1 ± 10.6 |
| Years of observation | 6.4 ± 3.4 | 6.1 ± 3.4 | 6.6 ± 3.4 |
| Years from last observation to DXA | 0.7 ± 1.2 | 0.7 ± 1.3 | 0.7 ± 1.1 |
| Femoral neck BMD (g/cm2) | 0.741 ± 0.149 | 0.778 ± 0.162 | 0.728 ± 0.144 |
| Femoral neck T-Score | −1.0 ± 1.4 | −0.7 ± 1.5 | −1.1 ± 1.3 |
| Total hip T-Score | −0.6 ± 1.3 | −0.3 ± 1.3 | −0.7 ± 1.3 |
| Lumbar spine T-Score | −0.9 ± 1.6 | −0.5 ± 1.6 | −1.1 ± 1.6 |
| DAS28ESRb | 4.1 ± 1.1 | 2.7 ± 0.4 | 4.5 ± 0.9 |
| CDAIb | 15.2 ± 8.8 | 7.0 ± 3.5 | 17.9 ± 8.4 |
-DAS28ESR: Disease activity score 28-joints with erythrocyte sedimentation rate; DXA: dual x-ray absorptiometry; RA: rheumatoid arthritis; BMI: body mass index; RF: rheumatoid factor; ACPA: anti-cyclic citrullinated peptide; csDMARD: conventional synthetic disease modifying anti-rheumatic drug; bDMARD: biologic DMARD; OP: osteoporosis; BMD: bone mineral density; CDAI: clinical disease activity index.
Low DAS28ESR ≤3.2, moderate/high DAS28ESR >3.2.
Calculated using trapezoidal area under the curve/observation time.
Calculated as proportion (%) of visits where participant was taking csDMARDs or bDMARDs.